EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Artificial intelligence and high-quality development in pharmaceutical manufacturing: evidence and mechanisms from Chinese listed firms

Yanan Zhu, Qiang Liu, Yuwen Chen

Frontiers in Public Health · 13.11.2026 · 14

DOI: 10.3389/fpubh.2026.1998133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 13.11.2026. Verfasst von Yanan Zhu und 2 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

As a strategic industry, pharmaceutical manufacturing bears not only on industrial economic development but also on the stability of drug supply and the resilience of public health systems. Yet the industry has long been constrained by heavy R&D investment, long development cycles, and low success rates, together with mounting quality-control pressure and rapidly growing public health needs. Artificial intelligence (AI) offers a promising route for easing these bottlenecks.

Methods

Using a sample of pharmaceutical manufacturing firms listed on China’s Shanghai and Shenzhen A-share markets from 2007 to 2024, this study constructs a firm-level index of high-quality development and examines how AI application is related to the high-quality development of pharmaceutical firms and through what channels.

Results

We find that AI application is significantly and positively associated with the high-quality development of listed pharmaceutical firms. This association is robust to alternative measures of AI, an instrumental-variable strategy, propensity score matching, lagged explanatory variables, and an index that excludes the development-scale dimension. Channel analyses suggest two routes: AI application is associated with stronger access to policy resources, measured by government subsidies, and with a higher share of highly skilled employees. Heterogeneity analyses show that the positive association is significant across life-cycle stages, regions, and ownership structures, with larger coefficients for mature firms and for firms in central and western China.

Discussion

This study provides firm-level evidence on AI application in pharmaceutical manufacturing and offers implications for policy design and technology strategies across firms.

Zitieren

APA

Zhu, Y., Liu, Q., & Chen, Y. (2026). Artificial intelligence and high-quality development in pharmaceutical manufacturing: evidence and mechanisms from Chinese listed firms. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1998133

Vancouver

Zhu Y, Liu Q, Chen Y. Artificial intelligence and high-quality development in pharmaceutical manufacturing: evidence and mechanisms from Chinese listed firms. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1998133

BibTeX
@article{Zhu2026,
  author = {Zhu, Yanan and Liu, Qiang and Chen, Yuwen},
  title = {Artificial intelligence and high-quality development in pharmaceutical manufacturing: evidence and mechanisms from Chinese listed firms},
  journal = {Frontiers in Public Health},
  year = {2026},
  volume = {14},
  doi = {10.3389/fpubh.2026.1998133}
}
Kostenlos starten →